Treatment of glomerulonephritides associated with hepatitis C virus infection

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 8, 2000, Pages 34-38

  Giannico, Giavanno ^a   Manno, Carlo ^a   Schena, Francesco Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; RIBAVIRIN; STEROID;

ANOREXIA; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; CRYOGLOBULINEMIA; DRUG MEGADOSE; DYSPNEA; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GLOMERULONEPHRITIS; HEMODIALYSIS PATIENT; HEMOLYTIC ANEMIA; HEMOPHILIA; HEPATITIS C; HUMAN; INFECTION RISK; INSOMNIA; INTRAVENOUS DRUG ABUSE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NAUSEA; NEPHROLOGY; PHARYNGITIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RASH;

EID: 0034486576     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.suppl_8.34     Document Type: Article

References (44)

1. Molecular biology of the hepatitis C viruses: Implication for diagnosis, development and control of virus disease
2. Epidemiology of HCV infection in the general population and in blood transfusion
3. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States
4. Two French genotypes of hepatitis C virus: Homology of the predominant genotype with the prototype American strain
5. Variability of hepatitis C virus
6. Type II IgM monoclonal cryoglobulinaemia and hepatitis C virus infection
7. Diffuse proliferative glomerulonephritis with hepatitis C virus-like particles in paramesangial dense deposits in a patient with chronic HCV hepatitis
8. Hepatitis C virus in patients with cryoglobulinemia type II
9. Hepatitis C infection and membranoproliferative glomerulonephritis
10. Membranoproliferative glomerulonephritis and hepatitis C virus infection
11. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection
12. Hepatitis C virus infection and membranous glomerulonephritis
13. Membranous glomerulonephritis in association with hepatitis C virus infection
14. Hepatitis C infection may be an important cause of membranoproliferative glomerulonephritis in Japan
15. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy
16. Hepatitis C virus-associated glomerulonephritis. Effect of α-interferon therapy
17. Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus
18. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France
19. Searching for hepatitis C virus antibodies in chronic primary glomerular disease
20. Is type II mixed globulinemia an essential part of hepatitis C virus (HCV) associated glomerulonephritis?
21. Hepatitis C virus infection and acute or chronic glomerulonephritis: An epidemiological and clinical appraisal
22. Prevalence of hepatitis C virus antibodies in primary glomerulonephritis in Brazil
23. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus
24. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy
25. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia
26. Hepatitis C virus and mixed cryoglobulinemias
27. Antibodies to hepatitis C virus in essential mixed cryoglobulinemia
28. A role for hepatitis C virus infection in type II cryoglobulinemia
29. Mechanism of action of interferons
30. Long-term response to higher dose of interferon (IFN) α-2b treatment of patients with chronic hepatitis C: A randomized multicenter trial
31. Therapy of hepatitis C. Meta-analysis of interferon α-2b trials
32. Combined interferon-2α, rimantadine hydrochloride and ribavirin inhibition of influenza virus replication in vitro
33. Therapy of hepatitis C: α interferon and ribavirin
34. What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicenter retreatment trial on ribavirin monotherapy versus combination with interferon
35. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
36. Interferon α2b alone or in combination with ribavirin for the treatment or relapse of chronic hepatitis C
37. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
38. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-α
39. Hepatitis C virus associated membranous glomerulonephritis
40. Focal segmental glomerulosclerosis associated with type C virus hepatitis and decrement of proteinuria by interferon-α therapy
41. Interferon α in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial
42. Interferon α-2a therapy in cryoglobulinemia associated with hepatitis C virus
43. Natural interferon-α versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study
44. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-α and ribavirin